Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02318719
Other study ID # DS5565-A-J304
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 2015
Est. completion date May 25, 2017

Study information

Verified date October 2020
Source Daiichi Sankyo, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Investigate the efficacy and safety of DS-5565 in subjects with Post-Herpetic Neuralgia (PHN) in comparison to placebo


Description:

[Double Blind Phase] The primary objective is to compare change in the Average Daily Pain Score (ADPS) from baseline to Week 14 in Asian subjects with PHN receiving DS-5565 versus placebo. [Open Extension Phase] The objective is to assess the long-term safety and efficacy of DS-5565 in subjects with PHN.


Recruitment information / eligibility

Status Completed
Enrollment 765
Est. completion date May 25, 2017
Est. primary completion date May 25, 2017
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: - PHN defined as pain present for more than 3 months after herpes zoster skin rash at screening - At screening, a pain scale of = 40 mm Exclusion Criteria: - Previous use of neurolytic block

Study Design


Intervention

Drug:
Placebo
Placebo
DS-5565


Locations

Country Name City State
Japan Medical Corporation Fujigaki Clinic Oita

Sponsors (3)

Lead Sponsor Collaborator
Daiichi Sankyo Co., Ltd. Quintiles, Inc., SRL Medisearch Inc.

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in the Average Daily Pain Score (ADPS) From Baseline to Week 14 Following Oral Administration of DS-5565 in Asian Participants With Post-herpetic Neuralgia Each participant recorded a pain score in the electronic patient diary once daily from the day after the screening visit (Visit 1) to the end of treatment/early termination visit (Visit 10). Prior to taking the study drug each morning, the participant selected the number that best described his or her pain over the past 24 hours on a scale of 0 (no pain) to 10 (worst possible pain). Higher ADPS scores indicated worse outcome. ADPS was the weekly average pain score based on the pain scores from the electronic patient diaries (Pain diary).
In this outcome, the change from baseline in ADPS is being reported with negative values representing improvements in average daily pain. The larger the negative value (ie. improvement), the greater the improvement in average daily pain.
Baseline to Week 14
Secondary Change in Visual Analog Scale (VAS) Pain From Baseline (Week 14) to Week 66 Following Administration of DS-5565 in Asian Participants With Post-herpetic Neuralgia Visual Analog Scale (VAS) pain is a 10-point assessment tool to measure pain levels, where 0 is defined as 'no pain' and 10 is defined as 'worst possible pain'. Higher VAS pain scores indicate worse outcome.
In this outcome, the change from baseline in VAS pain is being reported with negative values representing improvements in pain intensity. The larger the negative value (ie. improvement), the greater the improvement in pain intensity.
From baseline (Week 14) to Week 66
See also
  Status Clinical Trial Phase
Completed NCT01944150 - Association of Transcutaneous Electrical Nerve Stimulation and Hypnosis N/A
Completed NCT00159666 - Study of Pregabalin Therapy for Pain Relief in Subjects With Post-Herpetic Neuralgia Phase 4
Completed NCT00305357 - Evolution of Pain From Herpes Zoster
Not yet recruiting NCT03120962 - Effect of Early Use of Oxycodone During the Acute Phase of Herpes Zoster on Preventing Postherpetic Neuralgia N/A
Completed NCT02701374 - Efficacy and Safety of TRK-700 in Patient With Post-Herpetic Neuralgia Phase 2
Terminated NCT03094195 - Dose Response Study of EMA401 in Patients With Post-herpetic Neuralgia (PHN) Phase 2
Completed NCT01752699 - Methadone in Post-Herpetic Neuralgia Pain Phase 3
Completed NCT01250561 - Reduction of Postherpetic Neuralgia in Herpes Zoster N/A
Completed NCT02607280 - DS-5565 Phase III Study for Renal Impairment in Japanese Subjects Phase 3
Completed NCT01037088 - Effects of Vaporized Marijuana on Neuropathic Pain Phase 1/Phase 2
Completed NCT02633306 - Transcranial Magnetic Stimulation for Facial Pain N/A
Recruiting NCT05593237 - Transcranial Magnetic Stimulation for Chronic Neuropathic Pain N/A
Completed NCT01848730 - Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Post-herpetic Neuralgia Phase 2